Kenosha County Injectable Manufacturing Expansion

Lilly's $3 billion Kenosha County expansion of its recently acquired injectable-medicine manufacturing facility will add 750 highly skilled jobs for diabetes, obesity, device-assembly and packaging capacity. Construction was scheduled to begin in 2025. The prior Nexus acquisition, existing workforce, land and warehouse purchases, and the broader $4B Wisconsin program are excluded to avoid acquisition and rollup double counting.

Investment
$3.00B
Permanent jobs announced
750
Status
Under Construction
Opening timeline
Not yet announced
Why this project qualifies

With $3 billion in facility-specific investment and 750 permanent operating jobs announced, this project clears both of AFT's qualifying thresholds ($100 million in facility-specific investment OR 100 permanent operating jobs). This project also meets AFT's primary-source verification and physical U.S. manufacturing-footprint requirements.

View full methodology →
Why it matters

The pharmaceuticals context.

Pharmaceutical manufacturers are committing billions to new U.S. production capacity for active ingredients, injectable medicines, biologics and other high-demand treatments. North Carolina and Indiana remain major centers of investment, while new facilities are being planned across the South. The current project pipeline includes both large greenfield campuses and major expansions of established production sites.

Project record

At a glance

Company
Eli Lilly
Industry
Pharmaceuticals
Location
Pleasant Prairie, Wisconsin
Investment
$3.00B
Permanent jobs announced
750
Status
Under Construction
Announced
Dec 5, 2024
Opening timeline
Not yet announced
Added to tracker
Aug 30, 2026
Sources

Official references

Related

Other projects to know

Back to the tracker/projects/eli-lilly-kenosha-county-expansion